Concord Medical Regains Compliance with NYSE Minimum Price Requirement
Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a
healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New
York Stock Exchange (“NYSE”) dated August 6, 2024 (the “Compliance Notice”), notifying the Company that it is no longer considered below the
NYSE’s continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the “NYSE Minimum Price Requirement”).
As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance
standards due to the trading price of its American Depositary Shares. Following the receipt of the Compliance Notice, the Company is no longer considered
below the NYSE Minimum Price Requirement, and has regained compliance regarding this matter.